FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2107124419> ?p ?o ?g. }

• W2107124419 endingPage "527" @default.
• W2107124419 startingPage "517" @default.
• W2107124419 abstract "Uncertainties exist regarding the optimal treatment for vancomycin-resistant enterococcal (VRE) bloodstream infections, particularly in settings in which ampicillin cannot be used.Quinupristin-dalfopristin, linezolid, and daptomycin, all approved between 1999 and 2003, represent the mainstays of therapy for VRE bacteremia, although only linezolid has been specifically approved by the United States Food and Drug Administration for this indication. The main objective of this review is to compare the relative efficacies, dosing strategies, and side-effect profiles of quinupristin-dalfopristin, linezolid, and daptomycin for VRE bacteremia in the pediatric population. A brief description of recently approved broad-spectrum Gram-positive agents that may have a role in the management of VRE bacteremia in upcoming years is also provided.Linezolid, despite its bacteriostatic activity against VRE, may be the most versatile of the available drugs. It has activity against both Enterococcus faecalis and E. faecium, can be administered orally, and resistance appears to be less of a concern with linezolid compared with the other agents. Additionally, the results of two recent meta-analyses demonstrate more favorable outcomes with linezolid compared with daptomycin for the treatment of VRE bacteremia. The clinical pharmacokinetics of linezolid have been well described in children. The most notable concern with linezolid, however, is toxicities associated with prolonged use. Until more prospective data are available, we favor linezolid as first-line therapy for the treatment of VRE bacteremia in children." @default.
• W2107124419 created "2016-06-24" @default.
• W2107124419 creator A5028861765 @default.
• W2107124419 creator A5030280540 @default.
• W2107124419 date "2014-12-01" @default.
• W2107124419 modified "2023-09-27" @default.
• W2107124419 title "Optimizing therapy for vancomycin-resistant enterococcal bacteremia in children" @default.
• W2107124419 cites W1530035592 @default.
• W2107124419 cites W1692304524 @default.
• W2107124419 cites W1893972355 @default.
• W2107124419 cites W1930006472 @default.
• W2107124419 cites W1966573839 @default.
• W2107124419 cites W1967055281 @default.
• W2107124419 cites W1967730161 @default.
• W2107124419 cites W1970747983 @default.
• W2107124419 cites W1971883952 @default.
• W2107124419 cites W1972132078 @default.
• W2107124419 cites W1973427448 @default.
• W2107124419 cites W1977069647 @default.
• W2107124419 cites W1978377718 @default.
• W2107124419 cites W1980535030 @default.
• W2107124419 cites W1981669571 @default.
• W2107124419 cites W1982929150 @default.
• W2107124419 cites W1985635789 @default.
• W2107124419 cites W1987205592 @default.
• W2107124419 cites W1987977747 @default.
• W2107124419 cites W1988279180 @default.
• W2107124419 cites W1990448757 @default.
• W2107124419 cites W1993578606 @default.
• W2107124419 cites W1994368411 @default.
• W2107124419 cites W1995489787 @default.
• W2107124419 cites W2000101052 @default.
• W2107124419 cites W2000206740 @default.
• W2107124419 cites W2001349636 @default.
• W2107124419 cites W2002249283 @default.
• W2107124419 cites W2004207935 @default.
• W2107124419 cites W2007480979 @default.
• W2107124419 cites W2009289882 @default.
• W2107124419 cites W2011005625 @default.
• W2107124419 cites W2012901750 @default.
• W2107124419 cites W2015334010 @default.
• W2107124419 cites W2015727254 @default.
• W2107124419 cites W2016947697 @default.
• W2107124419 cites W2017719546 @default.
• W2107124419 cites W2018374001 @default.
• W2107124419 cites W2022039239 @default.
• W2107124419 cites W2024737812 @default.
• W2107124419 cites W2025385200 @default.
• W2107124419 cites W2025744614 @default.
• W2107124419 cites W2028653303 @default.
• W2107124419 cites W2028991203 @default.
• W2107124419 cites W2031499715 @default.
• W2107124419 cites W2032784320 @default.
• W2107124419 cites W2033466497 @default.
• W2107124419 cites W2034775604 @default.
• W2107124419 cites W2035466671 @default.
• W2107124419 cites W2039045692 @default.
• W2107124419 cites W2039371528 @default.
• W2107124419 cites W2041225480 @default.
• W2107124419 cites W2042004509 @default.
• W2107124419 cites W2042630144 @default.
• W2107124419 cites W2042757471 @default.
• W2107124419 cites W2043665687 @default.
• W2107124419 cites W2047649930 @default.
• W2107124419 cites W2048200680 @default.
• W2107124419 cites W2049090188 @default.
• W2107124419 cites W2051677268 @default.
• W2107124419 cites W2051817678 @default.
• W2107124419 cites W2054823241 @default.
• W2107124419 cites W2057091211 @default.
• W2107124419 cites W2057343867 @default.
• W2107124419 cites W2060864608 @default.
• W2107124419 cites W2061179636 @default.
• W2107124419 cites W2061819188 @default.
• W2107124419 cites W2064351339 @default.
• W2107124419 cites W2066180116 @default.
• W2107124419 cites W2067330050 @default.
• W2107124419 cites W2067752411 @default.
• W2107124419 cites W2068398959 @default.
• W2107124419 cites W2072828310 @default.
• W2107124419 cites W2073016376 @default.
• W2107124419 cites W2073442625 @default.
• W2107124419 cites W2073683411 @default.
• W2107124419 cites W2075038827 @default.
• W2107124419 cites W2077608176 @default.
• W2107124419 cites W2079154850 @default.
• W2107124419 cites W2081307324 @default.
• W2107124419 cites W2082476368 @default.
• W2107124419 cites W2084575882 @default.
• W2107124419 cites W2084873537 @default.
• W2107124419 cites W2085752562 @default.
• W2107124419 cites W2087865186 @default.
• W2107124419 cites W2088733747 @default.
• W2107124419 cites W2089324618 @default.
• W2107124419 cites W2089885764 @default.
• W2107124419 cites W2090610542 @default.
• W2107124419 cites W2091013565 @default.
• W2107124419 cites W2095110792 @default.

• next